Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to loss of $0.93 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly…
